ABBV · Q3 FY2026
AbbVie Inc. Q3 FY2026 earnings analysis
By SageNoodle Healthcare DeskNeutral
| Metric | Actual | Estimate | Result |
|---|---|---|---|
| Revenue | Not disclosed in the attached Q3 release | Q3 FY2025: $15.78B (yr ago) | Miss |
| EPS | Not disclosed in the attached Q3 release | Q3 FY2025: $0.10/share (yr ago) | Miss |
| Free Cash Flow | Not disclosed in the attached Q3 release | Q3 FY2025: $6.64B (yr ago) | Miss |
| Gross Margin | Not disclosed in the attached Q3 release | Not available: quarterly table reports no gross-margin values | Miss |
| Operating Margin | Not disclosed in the attached Q3 release | Q3 FY2025: 12.07% (yr ago) | Miss |
What changed
The attached Q3 release provides adjusted EPS guidance that includes $216 million of acquired IPR&D and milestones expense, lowering the company’s 2026 adjusted diluted EPS range to $13.76–$13.96. It does not provide Q3 actual revenue, EPS, cash flow or margins, so this evidence cannot establish whether operating performance beat or missed the year-ago quarter.
Impact on the investment thesis
No fair-value change: the release changes the stated 2026 adjusted EPS range, but supplies no Q3 results or other evidence sufficient to revise the prior $246.70 base value.
Full analysis: AbbVie stock: acquired R&D costs trim its 2026 EPS range
Explore AbbVie Inc. research →